Enhanced photo(geno)toxicity of demethylated chlorpromazine metabolites

Fecha de publicación:

Autores de IIS La Fe

  • Guillermo Garcia Lainez

    Autor

  • María Dolores Coloma Marco

    Autor

  • Justo Javier Escobar Cubiella

    Autor

Participantes ajenos a IIS La Fe

  • Palumbo F
  • Limones-Herrero D
  • Jiménez MC
  • Miranda MA

Grupos

Abstract

Chlorpromazine (CPZ) is an anti-psychotic drug widely used to treat disorders such as schizophrenia or manic depression. Unfortunately, CPZ exhibits undesirable side effects such as phototoxic and photoallergic reactions in humans. In general, the influence of drug metabolism on this type of reactions has not been previously considered in photosafety testing. Thus, the present work aims to investigate the possible photo(geno)toxic potential drug metabolites, using CPZ as an established reference compound. In this case, the metabolites selected for the study are demethylchlorpromazine (DMCPZ), didemethylchlorpromazine (DDMCPZ) and chlorpromazine sulfoxide (CPZSO). The demethylated CPZ metabolites DMCPZ and DDMCPZ maintain identical chromophore to the parent drug. In this work, it has been found that the nature of the aminoalkyl side chain modulates the hydro-phobicity and the photochemical properties (for instance, the excited state lifetimes), but it does not change the photoreactivity pattern, which is characterized by reductive photodehalogenation, triggered by homolytic carbon-chlorine bond cleavage with formation of highly reactive aryl radical intermediates. Accordingly, these metabolites are phototoxic to cells, as revealed by the 3T3 NRU assay; their photo-irritation factors are even higher than that of CPZ. The same trend is observed in photogenotoxicity studies, both with isolated and with cellular DNA, where DMCPZ and DDMCPZ are more active than CPZ itself. In summary, side-chain demethylation CPZ, as a consequence of Phase I biotransformation, does not result a photodetoxification. Instead, it leads to metabolites that exhibit in an even enhanced photo(geno)toxicity. (C) 2016 Elsevier Inc. All rights reserved.

Datos de la publicación

ISSN/ISSNe:
0041-008X, 1096-0333

Toxicology and applied pharmacology  ACADEMIC PRESS INC ELSEVIER SCIENCE

Tipo:
Article
Páginas:
131-137
PubMed:
27984131
Factor de Impacto:
1,496 SCImago
Cuartil:
Q1 SCImago

Citas Recibidas en Web of Science: 14

Documentos

  • No hay documentos

Métricas

Filiaciones mostrar / ocultar

Keywords

  • Comet assay; Excited states; Laser flash photolysis; Metabolites; Photosensitized DNA damage; Phototoxicity

Proyectos y Estudios Clínicos

RED DE SALUD MATERNO-INFANTIL Y DEL DESARROLLO

RD08/0072/0022 . INSTITUTO DE SALUD CARLOS III; FUNDACIÓN PARA LA INVESTIGACIÓN DEL HOSPITAL UNIVERSITARIO LA FE DE LA COMUNIDAD VALENCIANA . 2008

INMADUREZ HEPATICA Y VARIABILIDAD DE LA RESPUESTA AL IBUPROFENO EN EL DUCTUS ARTERIOSO PERSISTENTE (DAP) DEL PREMATURO. ESTUDIO DE LA ACTIVIDAD CYP-450 EN PREMATUROS.

Investigador Principal: MÁXIMO VENTO TORRES

AP-203/10 . 2010

PROTECCION FRENTE AL ESTRES OXIDATIVO DE LOS PREMATUROS ALIMENTADOS CON LECHE MATERNA DONADA PROCESADA EN EL BANCO DE LECHE DEL HOSPITAL LA FE

Investigador Principal: MARÍA JOSÉ GORMAZ MORENO

GE-006/10 . 2010

ALTERACIONES METABONOMICAS EN EL PREMATURO EXTREMO DEPENDIENTES DE LA CARGA DE OXIGENO RECIBIDA EN LA REANIMACION POSTNATAL: UN ESTUDIO PROSPECTIVO ALEATORIZADO.

Investigador Principal: MÁXIMO VENTO TORRES

PI11/00313 . INSTITUTO DE SALUD CARLOS III . 2012

DEVELOPMENT OF A MECHANISTICALLY-BASED CELL ASSAY FOR ANTICIPATING THE PHOTOGENOTOXIC POTENTIAL OF BIOACTIVE CHEMICALS AND THEIR METABOLITES

CP11/00154 . INSTITUTO DE SALUD CARLOS III; FUNDACIÓN PARA LA INVESTIGACIÓN DEL HOSPITAL UNIVERSITARIO LA FE DE LA COMUNIDAD VALENCIANA . 2012

MULTICENTER, RANDOMIZED, BLINDED CLINICAL STUDY COMPARING EARLY USE OF TOTAL BODY MODERATE HYPOTHERMIA PLUS TOPIRAMATE OR PLACEBO IN ASPHYXIATED NEWBORN INFANTS EVOLVING TO MODERATE-TO-SEVERE HYPOXIC ISCHEMIC ENCEPHALOPATHY

Investigador Principal: MÁXIMO VENTO TORRES

EC11-244 . INSTITUTO DE SALUD CARLOS III; FUNDACIÓN PARA LA INVESTIGACIÓN DEL HOSPITAL UNIVERSITARIO LA FE DE LA COMUNIDAD VALENCIANA . 2012

RED DE SALUD MATERNO INFANTIL Y DEL DESARROLLO

Investigador Principal: MÁXIMO VENTO TORRES

RD12/0026/0012 . INSTITUTO DE SALUD CARLOS III; FUNDACIÓN PARA LA INVESTIGACIÓN DEL HOSPITAL UNIVERSITARIO LA FE DE LA COMUNIDAD VALENCIANA . 2013

Cita

Compartir